Cullinan Management, Inc. CGEM 深 滬
等待開盤 11-26 09:30:00 美东时间
11.79
-1.140
-8.82%
華盛通- 最 高12.98
- 今 開12.98
- 成交量 269.67万股
- 最 低 11.22
- 昨 收 12.93
- 總市值 6.96亿
- 52周最高 13.60
- 市盈率 靜 --
- 換手率 4.56%
- 52周最低 5.68
- 委 比 -77.62%
- 總股本 5907.44万
- 歷史最高 59.85
- 量 比 1.39
- 振 幅 13.61%
- 歷史最低 5.68
- 每 手 1
- 風險率 1.75%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | OSCR大涨超22%，白宫计划延长奥巴马医改补贴；加密财库公司BitMine大涨19.6%
OSCR大涨超22%，白宫计划延长奥巴马医改补贴；加密财库公司BitMine大涨19.6%，持有3%的ETH代币供应量>>
11-25 15:10
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Advanced Biomed (NASDAQ:ADVB) stock rose 29.6% to $0.48 during Monday'...
11-25 01:05
Cullinan Management Ends Development of CLN-617
Cullinan Management ( ($CGEM) ) has provided an announcement. On November 18, 2...
11-22 06:03
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
11-21 15:50
Taiho Oncology, Taiho Pharma And Cullinan Therapeutics Initiate Rolling Submission Of NDA To FDA Seeking Accelerated Approval Of Zipalertinib For NSCLC Treatment
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (NASDAQ:CGEM) today announced the companies have initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and
11-20 20:15
Cullinan Therapeutics Q3 EPS $(0.77) Beats $(0.95) Estimate
Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0.95) by 19.37 percent. This is a 22.22 percent decrease over losses of $(0.63) per share
11-06 20:23
Cullinan Management Unveils Promising CLN-049 Clinical Data
Cullinan Management ( ($CGEM) ) has shared an announcement. On November 3, 2025...
11-03 22:25
Cullinan Therapeutics To Present New Clinical Data From Phase 1 Study Of CLN-049, Investigational FLT3xCD3 Bispecific T Cell Engager, In Patients With r/r AMLand MDS, At AHS 2025
CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, regardless of FLT3 mutational status~30% CRc rate observed at clinically
11-03 22:23
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
Cullinan Therapeutics presented new preclinical data on CLN-978, a CD19xCD3 bispecific T cell engager, at ACR Convergence 2025. The data demonstrated that CLN-978 rapidly and deeply depletes B cells in vitro and in vivo across multiple autoimmune diseases, including rheumatoid arthritis, Sjögren's disease, and systemic lupus erythematosus. Preclinical studies in nonhuman primates and murine models showed dose-dependent B cell depletion and diseas...
10-25 15:01
